Existing investor Lilly Asia Ventures helped the genome editing technology developer push its overall funding past the $100m mark.
China-based genome editing technology provider EdiGene closed a RMB450m ($66.8m) series B round today that included Lilly Asia Ventures, a corporate venture capital vehicle for pharmaceutical firm Eli Lilly.
The round was led by VC firm 3H Health Investment and also featured Sequoia Capital China, Alwin Capital, Kunlun Capital and exiting investors including IDG Capital, Huagai Capital and Green Pine Capital Partners.
EdiGene has created gene editing platforms for haematopoietic stem cells and T cells, in addition to a drug…
